1114-P: Patient-Reported Outcomes (PROs) during a Study of Feasibility of Continuous Glucose Monitor (CGM) Use in Publicly Insured Youth with Type 2 Diabetes (T2D)

Abstract

Publicly insured youth of minority and lower SES backgrounds are disproportionately impacted by the burden of T2D. The role of CGM use in this population is understudied, and patient-reported outcomes are important to assess while examining feasibility and acceptability of CGM adoption. This study assessed PROs during a feasibility study of CGM use. Youth were provided or prescribed flash CGM using established clinic workflows; PROs were collected from youth and parents at baseline, 3 and 12-month visits using age-appropriate measures (PAID-diabetes distress; PedsQL-health-related quality of life; PROMIS Global Health; DTA-diabetes technology attitudes). Baseline and 3-month data are presented. Participants at baseline included 30 youth with T2D (M age 15.1 years; 53% female; 90% Hispanic; 60% Spanish-speaking; 87% using insulin; M HbA1C 10.2%); 19 parents completed PROs at baseline. Parents and youth had moderate-to-positive attitudes about diabetes technology. Youth endorsed fair levels of global health; and youth and parents endorsed fair general and diabetes-related health-related quality of life. These PROs point to potential areas for future study to understand sources of lower self-reported health and quality of life, and to develop tailored interventions to address PROs while supporting CGM use in publicly-insured youth with T2D. Disclosure M.L.Tanenbaum: None. S.Hanes: None. K.K.Hood: Consultant; Cecelia Health. D.M.Maahs: Advisory Panel; Medtronic, LifeScan Diabetes Institute, MannKind Corporation, Consultant; Abbott, Research Support; Dexcom, Inc. S.Shah: Research Support; Boehringer-Ingelheim, Takeda Pharmaceutical Co., Ltd.